New triple attack on pancreatic cancer shows promise in early trial

NCT ID NCT06384560

First seen Feb 20, 2026 · Last updated Apr 23, 2026 · Updated 6 times

Summary

This study is testing a combination of chemotherapy, immunotherapy, and targeted radiation before surgery for people with pancreatic cancer that can be removed. The goal is to see if this triple treatment helps patients live longer without the cancer coming back. About 66 adults with early-stage pancreatic cancer will take part. The treatment involves several steps and requires ongoing monitoring, so it is not a cure but aims to control the disease better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Erasmus University Medical Center

    RECRUITING

    Rotterdam, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Maastricht University Medical Center

    NOT_YET_RECRUITING

    Maastricht, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St. Antonius Ziekenhuis

    RECRUITING

    Nieuwegein, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.